1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)


Table 3: 
Intracranial bleeding complications and clinical outcome
Fragmented Thrombus (n = 24) (7.4%)Single Thrombus (n = 300) (92.6%)P
Symptomatic intracranial hemorrhage (No.) (%)3 (12.5)17 (5.7).176
Asymptomatic intracranial hemorrhage (No.) (%)6 (25.0)34 (11.3).097
Favorable outcome (mRS 0–2) at 3 months (No.) (%)6/23 (26.1)171/286 (59.8).002
Death at 3 months (No.) (%)7/23 (30.4)43/292 (14.7).069